mrr pvt. Ltd.

Targeted Therapeutics - Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Press Release   •   Jan 23, 2017 15:11 IST

p { margin-bottom: 0.25cm; line-height: 120%; }a:link { }

GBI Research, the leading business intelligence provider, has released its latest research Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market. The report provides in-depth analysis of the major targeted therapeutics. The Market Drivers and Restraints for all the types of Targeted Therapeutics (TT) are analyzed.

The report provides comprehensive assessment of key pipeline therapies in the TT segment. The profiles of key promising molecules in the pipeline are mentioned. The regulatory Landscape is analyzed with focus on European and the US scenario. The regulatory landscape details about the major agencies for gene and stem cell therapies. The report profiles all the key companies dealing in TT with main focus on their deals involving M&A and licensing deals.

GBI Research finds that TT is the need of the hour for biotech and pharmaceutical companies to recover from the loss of revenue by patent expiry of conventional blockbuster drugs. Thus key pipeline molecules and key deals will help the companies to make a better future strategy.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The report gives insight about the key deals which have taken place between biopharmaceutical companies and their influence. Reasons for considering strategic consolidation as the main objective of the companies have been mentioned. The major types of TT include small molecule drugs, protein/peptide therapeutics, monoclonal antibody therapeutics, RNA interference, gene therapy and stem cell therapy.

The market drivers and restraints for these six classes are mentioned. From a commercial perspective there is a huge unmet medical need in difficult to treat diseases like cancer and autoimmune diseases. The unmet need is due to the lack of effective and efficacious therapies based on conventional mode of research. TT has the potential to satisfy this unmet need by being more efficacious, effective and safe. The strategic M&A deals and licensing deals of key companies such as Eli Lilly, Forest Laboratories, Hoffmann La-Roche, Isis Pharmaceuticals, J&J, Pfizer , Biogen, Antisoma and others are analyzed.

Download Sample Copy of This Report at: http://www.marketresearchreports.biz/sample/sample/3213